Pacira BioSciences (PCRX) news
Recent news
Pacira Biosciences, Inc.: Truist Securities cuts to hold from buy; raises target price to $36.5 from $31
AInvest Wire · 5d agoPacira Biosciences, Inc.: H.C. Wainwright cuts to neutral rating
H.C. Wainwright has revised its rating for Pacira BioSciences, Inc. (PCRX) from "Buy" to "Neutral," reflecting a shift in analyst sentiment regarding the company’s stock performance and outlook. The move comes amid mixed financial results and evolving market conditions for the specialty drug…
AInvest Wire · 5d agoPacira Biosciences, Inc.: Jefferies cuts to hold from buy
Jefferies & Co. has downgraded its rating for Pacira BioSciences, Inc. (Nasdaq: PCRX) from "Buy" to "Hold," citing recent developments in the company's strategic direction and market dynamics. The move follows Pacira's announcement of its pending acquisition by Viatris Inc. (Nasdaq: VTRS), a global…
AInvest Wire · 5d agoMoody's Ratings says Viatrix' acquisition of Pacira Biosciences boosts its presence in acute pain management, ratings not impacted
AInvest Wire · 6d agoPacira Biosciences, Inc.: Needham cuts to hold from buy
AInvest Wire · 6d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.